Floatz logo

Eptifibatide

Stroke Disorder

Arthur Pancioliprotein_peptidePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
65/ 100

Competitive context

128 Active assets in the Stroke Disorder cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
Incobotulinumtoxina
Parc de Salut Mar
Phase 4BBB
Atenolol
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB

View all 50 →

Same molecule, other indications

Eptifibatide is also rated in:

brain infarctionDormant
B
Indicative · Phase 2
62 / 100
View asset →
ischemic strokeActive
B
Indicative · Phase 3
59 / 100
View asset →
sickle cell diseaseDormant
CC
Indicative · Phase 1/2
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →